Stock Screener App

Frei -

Installieren

24.20

1.34% 0.32

Vorhandelsmarkt: 24.65 0.45 +1.86%

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire

RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. - The AI Journal

Stock Traders Buy Large Volume of Ultragenyx Pharmaceutical Put Options (NASDAQ:RARE) - MarketBeat

STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Ultragenyx Pharmaceutical Inc. (RARE) - marketscreener.com

Candriam S.C.A. Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. (INO) - GlobeNewswire Inc.

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit - The Malaysian Reserve

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile

RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ... - Caledonian Record

RARE Class Action Notice: Robbins LLP Reminds Investors of - GlobeNewswire

Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies - BioSpace

Ultragenyx Pharmaceutical Class Action Lawsuit Announced - Intellectia AI

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Ultragenyx Pharmaceutical (RARE) resubmits biologics license application for gene therapy treatment - MSN

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN

RARE SHAREHOLDER ACTION: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - TMX Newsfile

Quant snapshot: Manulife, KBC, Ambev lead strong buys as Ultragenyx, Atomera lag - Seeking Alpha

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire

2026-02-08 | RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse

INVESTOR NOTICE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire

Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment - Finviz

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - The Malaysian Reserve

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With - GuruFocus

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again - CGTLive®

13 Best Revenue Growth Stocks to Buy Right Now - Insider Monkey

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire

Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE) - marketscreener.com

RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com

RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire

Ultragenyx Pharmaceutical Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – RARE - marketscreener.com

2026-02-06 | RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - The Malaysian Reserve

Ultragenyx Pharmaceutical Class Action Reminder for Investors - Intellectia AI

RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc. - PR Newswire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - PharmiWeb.com

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with - PharmiWeb.com

Ultragenyx Pharmaceutical Class Action Lawsuit Notification - Intellectia AI

Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc. - Intellectia AI

ULTRAGENYX ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update - marketscreener.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical - GlobeNewswire

Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm - PharmiWeb.com

Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA - MSN

Cell therapy weekly: advocacy groups push to restore Tecartus access - RegMedNet

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz

Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights - Chartmill

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) ... - Caledonian Record

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

A Look At Ultragenyx Pharmaceutical (RARE) Valuation After UX111 Data And BLA Resubmission - Yahoo Finance

Did Positive UX111 Gene Therapy Data And FDA Resubmission Just Shift Ultragenyx Pharmaceutical's (RARE) Investment Narrative? - Yahoo Finance

Ultragenyx Pharmaceutical (RARE) Expected to Announce Earnings on Thursday - MarketBeat

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE) - The Globe and Mail

Ultragenyx Faces Shareholder Class Action Lawsuit - Intellectia AI

Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead the Ultragenyx Class Action Lawsuit – RGRD Law - marketscreener.com

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit - The AI Journal

RPRX

$44.21

0.36%

ROIV

$27.35

1.16%

INCY

$100.05

8.24%

BNTX

$108.93

1.28%

INSM

$148.55

0.66%

ONC

$353.43

1.31%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters